Interview With Douglas K. Gordon

In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
They are doing this in three ways.

First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.

Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.

And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.

Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).

#Delic #Psychedelics #Ketamine

In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

Perhaps, psychedelics can treat mental health issues in general.

Perhaps, ketamine can be used to heal.

In the conversation, MDMA to treat addiction was also discussed.

Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

#Psychedelics #Awakn #PsychedelicStocks

How long until Psychedelic Stocks Payoff?🍄🚀

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

Or, translated to Reddit-speak: when moon?

To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

The first will happen relatively soon.

#PsychedelicStocks #MindMed #Cybin

MindMed’s Financial Results & Business Update for Q2 2021 are out!
In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
This was an important, transitional quarter for the company for several reasons.

First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

Pertinent links:

MindMed’s CEO Jr Rahn Steps Down:
https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

Project Angie Update:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

MindMed’s Collaboration with NextStage Therapeutics:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

MindMed’s Pharmacogenetic Study:
https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

MMED’s Q2 Financial Results & Business Update:
https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedStock #MNMD